Workflow
Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
TeamTeam(US:TISI) Newsfile·2025-03-26 07:15

Core Insights - Defence Therapeutics Inc. has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025, to enhance its management team and accelerate development programs [2][3] - Dr. Theodorou brings over 25 years of experience in cancer research and innovative drug delivery systems, which aligns with Defence's mission to advance its proprietary Accum® technology [3][4] - The company has granted Dr. Theodorou 350,000 incentive stock options, with 100,000 vesting immediately and the remainder vesting in one year, exercisable at $1.07 per share for ten years [3] Company Overview - Defence Therapeutics is a clinical-stage biotechnology company focused on developing radio-immuno-conjugate and antibody-drug conjugate (ADC) products using its proprietary platform [4] - The core technology, Accum®, enables precision delivery of therapeutic agents to target cells, aiming to improve efficacy against cancer and infectious diseases [5]